Diabetes patients on insulin sensitizers have lower PAD risk

06/12/2013 | Medscape (free registration)

Data on 1,479 patients with type 2 diabetes and stable coronary disease revealed 24.1% of those who received insulin-providing medications to regulate blood glucose levels developed peripheral arterial disease at 4.6 years, compared with 16.9% in those who took insulin-sensitizing drugs. Researchers also found patients on insulin sensitizers showed reduced rates of amputation, lower-extremity revascularization and low ankle-brachial index than those who received insulin-providing drugs. The results appear in Diabetes Care.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC